Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Josep M. Llovet, MD, PhD
Advertisement
Articles by Josep M. Llovet, MD, PhD
Josep M. Llovet, MD, PhD, discusses the evolution of treatment options for patients with hepatocellular carcinoma.
Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Expert Discusses Treatment Options for HCC According to Disease StagePublished: February 14th 2019 | Updated:
New Agents Shake Up Treatment Landscape for Patients With HCCPublished: June 17th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
